Literature DB >> 12672231

Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.

Søren Ebdrup1, Ingrid Pettersson, Hanne B Rasmussen, Heinz-Josef Deussen, Anette Frost Jensen, Steen B Mortensen, Jan Fleckner, Lone Pridal, Lars Nygaard, Per Sauerberg.   

Abstract

A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed. The convergent synthetic procedure was based on a novel enzymatic kinetic resolution step. The conformation of ragaglitazar bound to the hPPARgamma receptor was quite different compared to the single-crystal structures of the l-arginine salt of ragaglitazar. In particular, the phenoxazine ring system had varying orientations. Ragaglitazar had high affinity for the hPPARalpha and -gamma receptors with IC(50) values of 0.98 and 0.092 microM, respectively. The lack of hPPARdelta activity could be explained by the absence of binding in the tail-up pocket in the hPPARdelta receptor, in contrast to the hPPARdelta agonist GW2433, which was able to bind in both the tail-up and tail-down pockets of the receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672231     DOI: 10.1021/jm021027r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Efficient synthesis of d-phenyllactic acid by a whole-cell biocatalyst co-expressing glucose dehydrogenase and a novel d-lactate dehydrogenase from Lactobacillus rossiae.

Authors:  Xi Luo; Yingying Zhang; Longfei Yin; Weilong Zheng; Yongqian Fu
Journal:  3 Biotech       Date:  2019-12-10       Impact factor: 2.406

Review 2.  Activation of PPARδ: from computer modelling to biological effects.

Authors:  Shirin Kahremany; Ariela Livne; Arie Gruzman; Hanoch Senderowitz; Shlomo Sasson
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  Dandamycin and chandrananimycin E, benzoxazines from Streptomyces griseus.

Authors:  Emma C Barnes; Patricia Bezerra-Gomes; Markus Nett; Christian Hertweck
Journal:  J Antibiot (Tokyo)       Date:  2015-02-18       Impact factor: 2.649

4.  Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein.

Authors:  Jeremy Fidelak; Silvia Ferrer; Michael Oberlin; Dino Moras; Annick Dejaegere; Roland H Stote
Journal:  Eur Biophys J       Date:  2010-05-23       Impact factor: 1.733

5.  Enzymological characterization of a novel d-lactate dehydrogenase from Lactobacillus rossiae and its application in d-phenyllactic acid synthesis.

Authors:  Xi Luo; Yingying Zhang; Fengwei Yin; Gaowei Hu; Qiang Jia; Changsheng Yao; Yongqian Fu
Journal:  3 Biotech       Date:  2020-02-06       Impact factor: 2.406

6.  Pharmacophore modeling and parallel screening for PPAR ligands.

Authors:  Patrick Markt; Daniela Schuster; Johannes Kirchmair; Christian Laggner; Thierry Langer
Journal:  J Comput Aided Mol Des       Date:  2007-10-25       Impact factor: 3.686

7.  Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.

Authors:  Ying Ma; Shu-Qing Wang; Wei-Ren Xu; Run-Ling Wang; Kuo-Chen Chou
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

8.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964

9.  Virtual Screening as a Technique for PPAR Modulator Discovery.

Authors:  Stephanie N Lewis; Josep Bassaganya-Riera; David R Bevan
Journal:  PPAR Res       Date:  2009-09-02       Impact factor: 4.964

10.  Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.

Authors:  Lei Liu; Ying Ma; Run-Ling Wang; Wei-Ren Xu; Shu-Qing Wang; Kuo-Chen Chou
Journal:  Drug Des Devel Ther       Date:  2013-04-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.